To Evaluate the Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an open, multicenter study of stage Ia/Ib in Chinese subjects with unresectable
locally advanced/metastatic solid tumors. It is divided into dose escalation period and
cohort expansion period. A total of 9 dose groups (Q3W on the first day of intravenous
administration every three weeks) were designed in the dose escalation period. The initial
dose was 1.0mg/kg, Q3W, and the observation period of DLT was 21 days. In the dose expansion
phase, 5 cohorts were set up.